Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of SPN 812 ER 100 and 200 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial

Next Previous
X
Search
Trial Profile

Evaluation of SPN 812 ER 100 and 200 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Viloxazine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Supernus Pharmaceuticals

    • Most Recent Events

    • 15 Sep 2021 Results of post-hoc analysis of four studies (NCT03247530, NCT03247517, NCT03247543 & NCT03247556) assessing the effect of viloxazine extended-release capsules on executive function deficits in pediatric subjects with attention-deficit/hyperactivity disorder published in the Pediatric Drugs
    • 16 Jul 2021 Results (n=495) of data from four studies (NCT03247530, NCT03247543, NCT03247517 and NCT03247556) assessing development of PK model to describe the PK profile of viloxazine and its major metabolite 5-HVLX-gluc in pediatric individuals with ADHD, published in the Journal of Clinical Pharmacology
    • 10 May 2021 Results of post hoc pooled analysis assessing clinical relevance (benefits and tolerabilit) of NCT03247530, NCT03247543, NCT03247517 and NCT03247556, pivotal phase 3 trials in pediatric patients treated with viloxazine extended-release, published in the International Journal of Clinical Practice.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top